ONCOVIX™-TOL
PERSONALIZED IMMUNOREGULATION
When the immune system loses balance, remains hyperreactive, or compromises native tissues.
1 PROTOCOL · 1 PATIENT
ONCOVIX™-TOL organizes a personalized clinical, immunological, and functional evaluation to understand the disease trajectory, flare patterns, therapeutic load, organic reserve, and opportunities for regulatory integration.
Immunological tolerance is not the absence of a response. It is a regulated, contextual, and proportional response.
What is ONCOVIX™-TOL?
ONCOVIX™-TOL is the personalized tolerogenic immunoregulation vertical of ONCOVIX™.
Its purpose is to integrate, for each patient, the diagnosis, immunological trajectory, organic compromise, current activity, flares, treatments, tolerance, functional reserve, and follow-up variables:
- Diagnosis and clinical phenotype
- Time of evolution & flare patterns
- Compromised organs and systems
- Autoantibodies & complement
- Previous and current treatments
- Response, dependence, or toxicity
- Infectious history & reactivation risk
- Nutritional & functional status
- Imaging & organ-specific tests
- Integration & follow-up opportunities
Beyond the diagnosis
The decisive question is not only what diagnosis the patient has, but what immunological pattern remains active and what balance needs to be rebuilt.
Learn how a case is evaluated
CLINICAL SCOPE
What patients can consult?
ONCOVIX™-TOL can evaluate different trajectories of autoimmunity, immune-mediated inflammation, and loss of regulation.
1. Systemic & Rheumatological
Rheumatoid arthritis, systemic lupus erythematosus, Sjögren's, systemic sclerosis, vasculitis, psoriatic arthritis.
2. Immune-mediated Neurological
Multiple sclerosis, demyelinating syndromes, myasthenia gravis, autoimmune neuropathies, autoimmune encephalitis.
3. Digestive & Hepatobiliary
Crohn's disease, ulcerative colitis, autoimmune hepatitis, primary biliary cholangitis, mucosal axis inflammation.
4. Dermatological & Respiratory
Psoriasis, atopic dermatitis, chronic urticaria, immune-mediated asthma, autoimmune interstitial lung disease.
5. Organ-specific & Endocrine
Autoimmune thyroiditis, Graves' disease, Type 1 diabetes, autoimmune cytopenias, immune-mediated nephritis.
6. Chronic Inflammation
Persistent conditions with pain, fatigue, recurrent flares, tissue compromise, or progressive loss of autonomy.
CLINICAL DEPTH
What does the evaluation reveal beyond the diagnosis?
The diagnosis identifies a disease. The ONCOVIX™-TOL evaluation seeks to understand how this immunological dysregulation is expressed and evolving in the current patient.
Activity Phenotype
Flares, persistence, partial remission, progression, or fluctuation over time.
Regulator-Effector Balance
Relationship between activation, control, and resolution signals.
Antigenic Context
Self, environmental, infectious, or tissue stimuli that can modulate the response.
Immunological Presentation
How antigen-presenting cells organize recognition and regulatory signals.
Cellular Axes & Cytokines
Integration of Treg, Th17, effector T cells, B cells, innate populations, IL-10, TGF-β.
Therapeutic Load & Reserve
Accumulated effect of treatments, organic state, nutritional status, and recovery capacity.
"Autoimmunity must be read as a dynamic network of recognition, regulation, tissue, metabolism, and memory."
The role of the current medical plan
ONCOVIX™-TOL recognizes the function of each component of the medical plan and organizes its integration within a multimodal strategy.
💊
Corticosteroids
Rapid control of inflammatory activity and acute compromise.
🛡️
DMARDs
Sustained control and reduction of activity according to the pathology.
🧬
Biologics
Targeted intervention on cytokines, receptors, or selected pathways.
🩺
Rehab
Organ preservation, recovery of autonomy, and quality of life.
ONCOVIX™-TOL Immunoregulatory Architecture
ONCOVIX™-TOL incorporates a regulatory reading that can complement dimensions not always addressed simultaneously within conventional treatment.
1. Membrane Microdomains
Organization of platforms where receptors, adhesion, and signaling converge.
2. Antigenic Context
Reading of self, tissue, and environmental signals relevant to the trajectory.
3. Regulatory Presentation
Integration of MHC-I and MHC-II pathways with proportional recognition context.
4. Costimulation / Co-inhibition
Functional balance of axes like CD80/CD86, CD28, CTLA-4, PD-1/PD-L1, IDO1.
5. Treg & Effectors
Integration of regulatory populations, Th17, effector T cells, and memory.
6. IL-10 / TGF-β Environment
Organization of signals associated with control, resolution, and tissue protection.
7. B Cells & Autoantibodies
Interpretation of the humoral component within the real clinical context.
8. Immune Traffic
Migration and cellular localization in compromised organs and tissues.
9. Immunometabolism & Redox
Relationship between energy, stress adaptation, and functional state of immune cells.
How is a case evaluated?
A structured 10-step process designed specifically for each patient.
1
Safety Check
Patient, diagnosis, allergies, infections.
2
Phenotype
Clinical, serological, or imaging criteria.
3
Trajectory
Onset, flares, progression, organs.
4
Therapeutic Map
DMARDs, biologics, responses, toxicities.
5
Functional Status
Organ function, nutrition, mobility.
6
Regulatory Gap
Covered dimensions & persistent activity.
How does it integrate with current treatment?
CURRENT MEDICAL PLAN
+
ONCOVIX™-TOL
+
STIP™ FOLLOW-UP
Multidisciplinary Coordination
Coordination may include Rheumatology, Immunology, Internal Medicine, Neurology, Gastroenterology, Pulmonology, Dermatology, Nephrology, Rehabilitation, and Nutrition.
- Preserve continuity of the treating team's plan.
- Identify safe windows for integration.
- Coordinate calendars and concomitant treatments.
- Differentiate immunological activity from accumulated damage.
- Track efficacy, tolerance, function, and safety.
Follow-up Variables (STIP™)
Follow-up integrates disease, function, safety, treatment, and time. Variables are selected according to the diagnosis and compromised organ.
Clinical Activity
Flares frequency, pain, fatigue, sleep, appetite.
Organ Function
Mobility, strength, gait, kidney/liver function.
Biomarkers
CRP, ESR, complement, autoantibodies.
Traceability
Biologic doses, infections, hospitalizations.
Evaluation and Admission Routes
Differentiated experience for patients/families and physicians/professionals.
Patients & Families
Essential Documents: Diagnosis, clinical summary, evolution time, current symptoms, treatments, rehab status.
Physicians & Professionals
Request history review, regulatory gap analysis, integration with DMARDs/Biologics, follow-up definition, or scientific meeting.
Frequently Asked Questions
What does TOL mean?
TOL identifies the tolerogenic vertical of ONCOVIX™, oriented towards the personalized evaluation of immunological balance and regulation of immune-mediated responses.
Do all patients with an autoimmune disease qualify?
Each case is reviewed individually. Qualification depends on documentation, activity, safety, organic reserve, clinical opportunity, and integration feasibility.
Can a patient be evaluated during a flare?
Yes. A flare may justify priority, but the evaluation must define clinical stability, organic compromise, infection risk, and safety conditions before planning.
Can it be integrated with corticosteroids, immunomodulators, or biologics?
The evaluation incorporates current treatment and organizes personalized coordination with the treating team.
Can a patient with pulmonary or neurological involvement consult?
Yes. These profiles require specialized evaluation, functional review, and close coordination with the treating team.
What does it mean to qualify?
It means that the history provides sufficient grounds to advance to a personalized evaluation and planning. Qualification does not represent a guaranteed clinical outcome.
YOUR CASE IS UNIQUE.
YOUR TREATMENT SHOULD BE TOO.
Request your personalized tolerogenic evaluation today.
🔬
Scientific focus
and real evidence
🎯
Personalized program
1 protocol · 1 patient
🔒
Confidentiality
and traceability
🌍
Coordinated international
attention
Scope Notice: The information presented is institutional, informative, and orientational in nature. The ONCOVIX™-TOL evaluation is developed based on the available history and is integrated with individual medical care and the indications of the treating team. Programmatic qualification does not constitute a guarantee of remission, cure, withdrawal of treatments, or any predetermined clinical outcome.